As a rapid-acting insulin, Merilog helps to lower mealtime blood sugar spikes to improve control of blood sugar in people with diabetes ... of Merilog to Sanofi (SNY)-Aventis U.S. Published ...

As a rapid-acting insulin, Merilog helps to lower mealtime blood sugar spikes to ... The FDA granted approval of Merilog to Sanofi-Aventis U.S. LLC. “The FDA has now approved three biosimilar insulin ...

Sanofi has moved a step closer to getting ... as an adjunct to insulin for patients with type 1 diabetes who can’t maintain blood glucose control using insulin alone, but only in patients ...

The drug, which is the first rapid-acting biosimilar, is meant to treat blood sugar spikes ... control in people with diabetes. Merilog (insulin-aspart-szjj, Sanofi-Aventis U.S.) was approved ...

(RTTNews) - The U.S. Food and Drug Administration announced that Sanofi-Aventis ... to lower mealtime blood sugar spikes to improve control of blood sugar in people with diabetes.

Metabolex has entered into an agreement with Sanofi–Aventis for the development of ... is in a Phase II trial for the treatment of type 2 diabetes (T2D). Metabolex will receive upfront and ...

Digital health company Health2Sync will work with Sanofi on digitising its range ... patients that is designed to help them improve blood glucose control by encouraging adherence – for example ...

Sanofi–Aventis has signed an agreement with CureDM ... islet neogenesis — for the treatment of type 1 and type 2 diabetes. The agreement for this preclinical-stage agent involves an upfront ...

Also Read: Sanofi/Johnson & Johnson ... Merilog helps lower mealtime blood sugar spikes and improve blood sugar control in people with diabetes. The approval is for a 3 milliliter (mL) single ...